Tango Therapeutics reported second quarter 2026 financial results on August 11, 2026. The company held $1.0 billion in cash as of June 30, 2026. Net loss for the three months ended June 30 was $55.3 million, or $0.37 per share, compared to a net loss of $38.9 million in the prior year period. Research and development expenses increased to $37.2 million from $32.8 million, while general and administrative expenses rose to $22.6 million from $11.3 million due to personnel-related costs. The company announced key leadership appointments, including Fatma Ocak as Chief Commercialization Officer effective August 17, 2026, and Robert Azelby as Chairman of the Board. Clinical updates highlighted a 92% objective response rate for vopimetostat combined with daraxonrasib in pancreatic cancer, supporting plans to advance into Phase 3 development.
